Revenue Breakdown
Composition ()
No data
Revenue Streams
McKesson Corp (MCK) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is U.S. Pharmaceutical, accounting for 83.8% of total sales, equivalent to $86.48B. Other significant revenue streams include Oncology & Multispecialty and Medical-Surgical Solutions. Understanding this composition is critical for investors evaluating how MCK navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, McKesson Corp maintains a gross margin of 3.43%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 1.42%, while the net margin is 1.13%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively MCK converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, MCK competes directly with industry leaders such as COR and CAH. With a market capitalization of $101.88B, it holds a leading position in the sector. When comparing efficiency, MCK's gross margin of 3.43% stands against COR's 3.23% and CAH's 3.49%. Such benchmarking helps identify whether McKesson Corp is trading at a premium or discount relative to its financial performance.
